Dermatology › Psoriatic Arthritis

Biologic & JAK Inhibitor Benefit-Risk Analysis for Psoriatic Arthritis

Psoriatic arthritis demands multi-domain BRA across six distinct mechanism classes: IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab), IL-23 blockers (guselkumab), JAK inhibitors (tofacitinib, upadacitinib, deucravacitinib/TYK2), TNF inhibitors, PDE4 inhibitors (apremilast), and emerging dual-pathway agents. ArcaScience delivers integrated benefit-risk analysis spanning joint, skin, enthesitis, dactylitis, nail, and axial domains.

See Platform Request Demo

1,000,000+

PsA patients in the US

2,100+

PsA clinical trials analyzed

Mechanism classes approved for PsA

30%+

Of psoriasis patients develop PsA

Disease Overview

Why Psoriatic Arthritis Multi-Domain Therapy Demands Specialized BRA

Psoriatic arthritis involves simultaneous inflammation across joints, skin, entheses, digits, nails, and spine, requiring multi-endpoint efficacy assessment against diverse safety profiles spanning cardiovascular risk, opportunistic infections, and paradoxical inflammatory reactions across six approved mechanism classes.

JAK Inhibitor MACE/VTE Risk

The ORAL Surveillance study revealed increased cardiovascular (MACE) and thromboembolic (VTE) events with tofacitinib versus TNF inhibitors in RA, triggering FDA boxed warnings class-wide across all JAK inhibitors. Comparative safety profiling of tofacitinib, upadacitinib, and deucravacitinib (TYK2-selective) in PsA populations requires dedicated BRA models that account for differing JAK selectivity and population-specific cardiovascular risk factors.

IL-17 Inhibitor Fungal Infections & IBD

IL-17 blockade with secukinumab, ixekizumab, and bimekizumab carries elevated Candida infection rates due to IL-17's critical role in mucocutaneous immunity. Additionally, IL-17 inhibitors are associated with new-onset or exacerbation of inflammatory bowel disease (IBD) and paradoxical psoriasis flares. BRA must quantify these mechanism-specific risks against multi-domain efficacy advantages in PsA.

Multi-Domain Efficacy-Safety Tradeoffs

PsA uniquely requires simultaneous assessment across joint (ACR), skin (PASI), enthesitis, dactylitis, nail, and axial spine domains. Not all mechanism classes perform equally across domains—IL-17 inhibitors excel in skin and enthesitis while JAK inhibitors offer broader multi-domain coverage. Treatment sequencing across mechanism classes after inadequate response demands integrated multi-endpoint BRA frameworks.

Platform Capabilities

How ArcaScience Addresses Psoriatic Arthritis BRA

Our modules are configured with PsA multi-domain trial data, JAK inhibitor cardiovascular risk models, and regulatory templates for biologic and targeted synthetic DMARD submissions.

Data Intelligence

PsA Multi-Domain Trial Data

2,100+ PsA clinical trials including DISCOVER-1/2, SPIRIT-P1/P2, SELECT-PsA-1/2, BE OPTIMAL/COMPLETE, and OPAL Broaden/Beyond programs. Comprehensive psoriasis-PsA overlap databases linking dermatology and rheumatology registries, with multi-domain outcome tracking across ACR, PASI, enthesitis, dactylitis, nail, and axial endpoints.

Explore Data Engine →

Decision Intelligence

MACE & Multi-Domain AI Models

AI-powered MACE risk stratification models comparing JAK inhibitors by selectivity profile, fungal infection prediction algorithms for IL-17 blockade, multi-domain response modeling across all six PsA disease manifestations, and treatment sequencing optimization to guide mechanism class selection after inadequate response.

Explore AI Models →

Automated Outputs

PsA Regulatory Outputs

PSURs with multi-domain safety sections covering joint, skin, and systemic adverse events. JAK inhibitor boxed warning compliance documents for FDA submissions. Biosimilar switching BRA for TNF inhibitor transitions. Comparative effectiveness reports across mechanism classes supporting HTA submissions and formulary positioning.

Explore Outputs →

Psoriatic Arthritis Intelligence

Platform Performance in Psoriatic Arthritis

7,800,000,000+

Rheumatology/dermatology data points

66%

Faster MACE signal detection

PsA-specific AI models deployed

PsA regulatory submissions supported

Case Evidence — Psoriatic Arthritis

JAK Inhibitor Cardiovascular Safety Profiling in PsA

Challenge

A pharma company needed to differentiate MACE and VTE risk profiles between tofacitinib and upadacitinib in PsA populations versus RA populations, given the class-wide boxed warning triggered by ORAL Surveillance data generated in an RA cohort with higher baseline cardiovascular risk.

Result

ArcaScience's AI models enabled population-specific MACE signal differentiation, demonstrating distinct cardiovascular risk trajectories in PsA vs. RA populations and providing evidence to support nuanced labeling discussions with FDA and EMA, with significantly improved VTE risk prediction accuracy.

3.7x

Faster MACE signal differentiation

39%

Improvement in VTE risk prediction accuracy

View All Case Studies →

The ability to differentiate MACE risk in our PsA population from the RA-derived ORAL Surveillance data was critical for our regulatory strategy. ArcaScience's models gave us the population-specific evidence we needed to have a more nuanced safety conversation with both FDA and EMA.

Head of Immunology Safety

Global Pharma Company

Frequently Asked Questions

Psoriatic Arthritis BRA

Our platform builds PsA-specific cardiovascular risk models that account for the distinct baseline risk profiles of PsA patients compared to the RA cohort studied in ORAL Surveillance. AI models stratify MACE and VTE risk by JAK selectivity (pan-JAK vs. JAK1-selective vs. TYK2-selective), patient age, cardiovascular comorbidities, and concomitant medications. This enables population-specific benefit-risk assessments rather than relying solely on class-wide extrapolations from RA data.

Yes. ArcaScience integrates clinical trial data from SPIRIT, MEASURE, and BE OPTIMAL programs with post-marketing surveillance databases to model new-onset and exacerbation of IBD events associated with IL-17 blockade. Our models identify patients at elevated IBD risk based on family history, subclinical gut inflammation biomarkers, and prior GI symptoms, enabling proactive risk stratification and supporting contraindication labeling decisions for secukinumab, ixekizumab, and bimekizumab.

PsA treatment algorithms often involve sequencing from TNF inhibitors to IL-17 inhibitors, IL-23 blockers, or JAK inhibitors after inadequate response. Our platform models cumulative safety exposure across sequential mechanism classes, predicting carry-over risks and washout-dependent adverse event patterns. This includes modeling the impact of prior TNF inhibitor exposure on subsequent IL-17 or JAK inhibitor safety profiles, enabling comprehensive benefit-risk evaluation for second- and third-line treatment positioning.

Absolutely. Many biologics approved for PsA also hold psoriasis indications, and up to 30% of psoriasis patients develop PsA. Our platform provides integrated benefit-risk analysis that spans both indications, linking dermatology trial data (PASI, IGA) with rheumatology endpoints (ACR, enthesitis resolution, dactylitis resolution). This dual-indication BRA supports unified labeling strategies, cross-indication safety signal detection, and regulatory submissions that address both dermatology and rheumatology review divisions simultaneously.

See ArcaScience Applied to Psoriatic Arthritis

Request a demonstration focused on psoriatic arthritis BRA. Our immunology and rheumatology scientists will present JAK inhibitor cardiovascular risk models, multi-domain efficacy-safety analysis, and treatment sequencing BRA frameworks across all six approved mechanism classes.

Request PsA Briefing Explore the Platform →